Details for Patent: 8,617,595

Which drugs does patent 8,617,595 protect, and when does it expire?

Patent 8,617,595 protects TEKTURNA and is included in one NDA.

Protection for TEKTURNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in twenty-two countries.

Summary for Patent: 8,617,595

Title:	Galenic formulations of organic compounds
Abstract:	The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Inventor(s):	Rigassi-Dietrich; Petra G (Therwil, CH), Schmid; Martin (Wettingen, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/590,398
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,617,595
Patent Claim Types: see list of patent claims	Compound; Dosage form; Use; Formulation; Process;

Drugs Protected by US Patent 8,617,595

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Noden Pharma	TEKTURNA	aliskiren hemifumarate	TABLET;ORAL	021985-001	Mar 5, 2007	AB	RX	Yes	No					Y
Noden Pharma	TEKTURNA	aliskiren hemifumarate	TABLET;ORAL	021985-002	Mar 5, 2007	AB	RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,617,595

PCT Information
PCT Filed	March 16, 2005	PCT Application Number:	PCT/EP2005/002798
PCT Publication Date:	September 29, 2005	PCT Publication Number:	WO2005/089729

International Family Members for US Patent 8,617,595

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	048431
Australia	2005224010
Australia	2009202069
Brazil	PI0508833